INT225312

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2008
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 7.91
Pain Relevance 0.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (Alcam)
Anatomy Link Frequency
CPA 2
plasma 1
SHED 1
Alcam (Mus musculus)
Pain Link Frequency Relevance Heat
wide dynamic range 2 65.44 Quite High
anesthesia 15 62.60 Quite High
Inflammation 9 59.72 Quite High
cytokine 4 52.60 Quite High
dexamethasone 2 47.12 Quite Low
Chronic pancreatitis 10 5.92 Low Low
ketamine 6 5.00 Very Low Very Low Very Low
isoflurane 6 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
backache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 1221 100.00 Very High Very High Very High
Colorectal Cancer 192 99.28 Very High Very High Very High
Residual Neoplasm 60 98.48 Very High Very High Very High
Pancreatic Cancer 118 98.24 Very High Very High Very High
Systemic Lupus Erythematosus 64 95.28 Very High Very High Very High
Adhesions 9 95.16 Very High Very High Very High
Adenocarcinoma 114 94.56 High High
Pancreatitis 24 91.24 High High
Apoptosis 35 87.68 High High
Immune System Diseases 8 84.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Circulating protein levels of ALCAM, ICAM1, and TIMP1 in the same mouse plasma used in the proteomic approach were measured by ELISA (Figure 5).
Gene_expression (levels) of ALCAM in plasma
1) Confidence 0.50 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504036 Disease Relevance 0.73 Pain Relevance 0
Elevated levels of ALCAM, IGFBP4, LCN2, and WFDC2 in circulation in pancreatic cancer are novel findings.
Gene_expression (levels) of ALCAM associated with pancreatic cancer
2) Confidence 0.43 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504036 Disease Relevance 1.17 Pain Relevance 0.06
Genes regulated by ALR include ECM-degrading enzyme, heparanase, uPA/PL, BH-protocadherin, L1CAM, ALCAM and Keratin17, consistent with decreased expression of these molecules.
Gene_expression (include) of ALCAM
3) Confidence 0.30 Published 2008 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2254332 Disease Relevance 0.37 Pain Relevance 0.03
Enrichment of ESA+CD44+CD166+ cells was even more striking and particularly evident when CD166 expression was analyzed on residual human ESA+CD44+ cells (Figures 1E, S1B & C).
Spec (analyzed) Gene_expression (expression) of CD166
4) Confidence 0.19 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 1.21 Pain Relevance 0
Consistent with the hypothesis that TG cells are more resistant to chemotherapy and the association between CD166 expression and poor outcome, the tumorigenic CD166+ subset of ESA+CD44+ cells appeared more resilient to not only CPA, but also Irinotecan.
Gene_expression (expression) of CD166 in CPA
5) Confidence 0.19 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.64 Pain Relevance 0
Human ESA+CD44+ cells from xenogeneic colorectal tumors can be further subdivided based on CD166 expression, resulting in enrichment for tumorigenic (TG) cells among the CD166+ population.
Gene_expression (expression) of CD166 associated with colorectal cancer
6) Confidence 0.19 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 1.19 Pain Relevance 0
We found that SHED are capable of differentiating into osteogenic and adipogenic cells, expressing mesenchymal surface molecules (STRO-1, CD146, SSEA4, CD73, CD105, and CD166), and activating multiple signaling pathways, including TGF?
Gene_expression (expressing) of CD166 in SHED
7) Confidence 0.18 Published 2010 Journal Stem Cell Res Ther Section Abstract Doc Link PMC2873699 Disease Relevance 0.34 Pain Relevance 0
Herein, we used flow cytometry, immunoblot analysis, and immunocytostaining analysis to demonstrate that SHED at passage 3 expressed many mesenchymal surface markers, including STRO-1, SSEA4, CD73, CD105, CD146, and CD166 but were negative for CD34 and CD45 (Figures 1A-C).
Gene_expression (expressed) of CD166
8) Confidence 0.18 Published 2010 Journal Stem Cell Res Ther Section Body Doc Link PMC2873699 Disease Relevance 0 Pain Relevance 0
Consistent with the elevated frequency of residual tumor cells expressing high levels of tumorigenicity-associated markers, such as CD166, relative expression of CoCSC-associated versus NTG-associated transcripts, such as ALDH1A1 and VIM, respectively, was further disparate in CPA- versus vehicle-treated control UM-C4 tumors (Figure 4B).
Gene_expression (expression) of CD166 in CPA associated with residual neoplasm and cancer
9) Confidence 0.17 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.48 Pain Relevance 0
Overexpressed in a number of epithelial tumors and suggested to be an important prognostic marker of tumor progression [44], CD166 (i.e.
Gene_expression (Overexpressed) of CD166 associated with cancer
10) Confidence 0.15 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.89 Pain Relevance 0
Not only did cells maintain ESA, CD44 and CD166 expression during in vitro culture (Figures 6A & B), but the ability to generate heterogeneous tumors resembling parental tumors was conserved as well (Figure 6C).
Gene_expression (expression) of CD166 associated with cancer
11) Confidence 0.15 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.88 Pain Relevance 0
Fluorescence-activated cell sorting analysis and sorting of SP cells
Gene_expression (analysis) of Fluorescence-activated cell sorting
12) Confidence 0.04 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2890558 Disease Relevance 0 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox